Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;15(7):597-606.
doi: 10.1111/1753-0407.13401. Epub 2023 May 4.

DiabetesWise: An innovative approach to promoting diabetes device awareness

Jessie J Wong  1 , Ananta Addala  1 , Sarah J Hanes  1 , Sara Krugman  2 , Diana Naranjo  1 , Sierra Nelmes  1 , Kyle Jacques Rose  3 , Molly L Tanenbaum  4   5 , Korey K Hood  1   2
Affiliations

DiabetesWise: An innovative approach to promoting diabetes device awareness

Jessie J Wong et al. J Diabetes. 2023 Jul.

Abstract
in English, Chinese

Background: DiabetesWise is an unbranded, data-driven online resource that tailors device recommendations based on preferences and priorities of people with insulin-requiring diabetes. The objective of this study is to examine whether DiabetesWise increases uptake of diabetes devices, which are empirically supported to improve glycemic and psychosocial outcomes.

Methods: The sample included 458 participants (Mage = 37.1, SD = 9.73; 66% female; 81% type 1 diabetes) with insulin-requiring diabetes and minimal diabetes device use at enrollment. Participants used DiabetesWise and completed online surveys. Chi-square and t tests evaluated requests for a device prescription, receiving a prescription, and starting a new device at 1 and 3 months post use. Baseline predictors of these variables and past use of continuous glucose monitors (CGMs) and changes in diabetes distress post use were also examined.

Results: Within the first month of interacting with DiabetesWise 19% of participants asked for a prescription for a diabetes device. This rate rose to 31% in the first 3 months. These requests resulted in 16% of the sample starting a new device within the first 3 months. Whereas several factors were associated with prior CGM use, receiving a prescription, and starting a new device, more diabetes distress (t(343) = -3.13, p = .002) was the only factor associated with asking for a prescription. Diabetes distress decreased after interacting with DiabetesWise within 1 month (t(193) = 3.51, p < .001) and 3 months (t(180) = 5.23, p < .001).

Conclusions: Within 3 months of interacting with DiabetesWise, one in three participants had requested a prescription for a new diabetes device and average distress levels were reduced, indicating benefit from this low-intensity online platform.

背景:DiabetesWise是一个无品牌的, 以数据驱动的在线资源, 根据胰岛素需求者的偏好和优先事项, 量身定制设备推荐。本研究的目的是研究DiabetesWise是否能增加胰岛素需求者使用胰岛素治疗设备的比率, 这些设备经过实证支持可改善血糖和心理社会结果。 方法:样本包括458名参与者(平均年龄=37.1岁, 标准差=9.73；66%女性；81%为1型糖尿病患者), 这些参与者在入组时使用胰岛素治疗且对糖尿病设备的使用较少。参与者使用DiabetesWise并完成在线调查。使用卡方检验和t检验评估使用DiabetesWise后1个月和3个月内器械处方请求, 接受处方和开始使用新设备的比率。还研究了这些变量的基线预测因素, 过去连续血糖监测(CGM)使用情况以及使用后糖尿病困扰变化。 结果:在与DiabetesWise互动的第一个月内, 有19%的参与者要求处方以获取糖尿病设备。在前三个月内, 这一比率上升至31%。这些要求导致了样本中16%的参与者在前三个月内开始使用新的设备。虽然几个因素与先前CGM使用, 接受处方和开始使用新设备有关, 但更多的糖尿病困扰(t(343)=-3.13, p=0.002)是要求处方的唯一相关因素。与DiabetesWise互动后, 一个月内(t(193)=3.51, p<0.001)和三个月内(t(180)=5.23, p<0.001), 糖尿病困扰程度减少。 结论:在与DiabetesWise互动的三个月内, 三分之一的参与者要求处方以获取新的糖尿病设备, 并且平均困扰程度降低, 表明这个低强度在线平台具有益处。.

Keywords: 1型糖尿病; 2型糖尿病; continuous glucose monitor (CGM); diabetes distress; insulin; insulin pump; type 1 diabetes; type 2 diabetes; 动态血糖监测; 糖尿病困扰; 胰岛素; 胰岛素泵.

PubMed Disclaimer

Conflict of interest statement

No potential conflicts of interest.

Figures

FIGURE 1
FIGURE 1
DiabetesWise home page. The DiabetesWise Check Up asks brief questions related to diabetes self‐management, priorities, and preferences and then provides data‐driven recommendations for device combinations and educational resources to learn more about those recommendations.
FIGURE 2
FIGURE 2
DiabetesWise's diabetes device finder. The Diabetes Device Finder allows users to browse and search for diabetes devices based on specific priorities. It also includes filters to select specific brands and/or devices.
FIGURE 3
FIGURE 3
Example of a personal story and account of diabetes management experience (“wisdom”) provided by DiabetesWise. DiabetesWise “wisdom” shares personal accounts of people's experiences with diabetes management, including personal preferences and lived experiences. These accounts highlight the varying and personalize nature of selecting devices and device combinations.
FIGURE 4
FIGURE 4
Number of prescription requests and receipt and new device uptake at 1 and 3 months.
See this image and copyright information in PMC

References

    1. Liberman A, Buckingham B. Diabetes technology and the human factor. Diabetes Technol Ther. 2016;18(Suppl 1):S101‐S111. doi:10.1089/dia.2016.2510 - DOI - PubMed
    1. Szypowska A, Ramotowska A, Dzygalo K, Golicki D. Beneficial effect of real‐time continuous glucose monitoring system on glycemic control in type 1 diabetic patients: systematic review and meta‐analysis of randomized trials. Eur J Endocrinol. 2012. Accessed March 29, 2022; http://www.ncbi.nlm.nih.gov/books/NBK98280/ 166:567‐574. - PubMed
    1. Langendam M, Luijf YM, Hooft L, DeVries JH, Mudde AH, Scholten RJ. Continuous glucose monitoring systems for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2012;2012:1. doi:10.1002/14651858.CD008101.pub2 - DOI - PMC - PubMed
    1. Weissberg‐Benchell J, Antisdel‐Lomaglio J, Seshadri R. Insulin pump therapy: a meta‐analysis. Diabetes Care. 2003;26(4):1079‐1087. doi:10.2337/diacare.26.4.1079 - DOI - PubMed
    1. Lin R, Brown F, James S, Jones J, Ekinci E. Continuous glucose monitoring: a review of the evidence in type 1 and 2 diabetes mellitus. Diabet Med. 2021;38(5):e14528. doi:10.1111/dme.14528 - DOI - PubMed